Deerfield Capital DFR
-
MAKO Surgical Hooked, But Not Gutted
By Stephen Simpson : Investors who have followed med-tech for a long time probably knew that this day was coming -- highly-valued MAKO Surgical ( MAKO ) disappointed the Street with its quarterly results, and the consequences in the market are going to be severe. Only zealots believed that MAKO ...
-
US CREDIT-CLOs ready for the mainstream: CIFC Deerfield CEO
NEW YORK, April 21 (Reuters) - Asset managers Deerfield Capital and Commercial Industrial Finance Corp recently closed their merger, forging a strengthened loan platform with the deep conviction that...
-
New Morningstar Analyst Report - ZymoGenetics, Inc.
… With several products in clinical development and costly commercialization efforts under way, ZymoGenetics has turned to Deerfield Capital Management for a $100 million credit line. However, even with the credit line, we think the firm will need to look …
-
Buy & Hold strategy & Technical Indicators - Seek Experts' responses
Request experienced investors' feedback on my strategy and data mining: I'm a small investor with a small diversified portfolio, preferring the "Buy & Hold" strategy of stocks & ETFs which provide reliable dividend returns (with a couple of exceptions). I have GE, MMM, BRK.B, RAI, TGT, EWM, DFR , CEO, PDT, and VLT at this time. The mutual funds I own are not listed nor an issue here. Primarily, but not exclusively, I watch the MACD, money flow index, and analysts opinions for the most part, but I am feeling that these data may not be as useful as some unknown (to me) techincal indicators I could be using (mindful I am not an active trader, preferring to buy&hold for the long term with decent dividends). I know there are strong opinions in both the pro- and anti- "buy & hold" camps; and in reality, I may just be only dollar-averaging when all is said and done. To you pros and experts, you may see that I am missing something in my thinking/research/investing process? All opinions and recommendations are welcome; I will, of course, make my own final investment judgements. Thank You.
-
Recothrom is off to a slow start, but we find ZymoGenetics' hep C candidate especially promising.
… With several products in clinical development and costly commercialization efforts under way, ZymoGenetics has turned to Deerfield Capital Management for a $100 million credit line. However, even with the credit line, we think the firm will need to look …
-
Dropping Coverage of Deerfield
We are dropping coverage of Deerfield Capital Corporation DFR to focus our resources elsewhere.
-
Mortgage REIT Woes Continue
We see no reason to alter our stance on iStar Financial SFI, Chimera Investment CIM, Deerfield Capital DFR , Gramercy Capital GKK, Newcastle Investment NCT, and Alesco Financial AFN, all of which operate (or have operated) as mortgage …
-
PSLCX Putnam Small Cap Value C Fund Analysis, Report, Research, 5 Star Rating – Morningstar
… services for real estate transactions, deteriorated in the housing market's collapse. Capital Trust CT and Deerfield Capital DFR also lost more than 85% of their value in 2008; manager Ned Shadek misjudged their leveraged business models …
-
No Bailout for the Mortgage REITs
We see no reason to alter our negative stance on iStar Financial SFI, Chimera Investment CIM, Deerfield Capital DFR , Gramercy Capital GKK, Newcastle Investment NCT, and Alesco Financial AFN, even as the U.S. government has moved much more …
-
Mortgage REITS Face Difficult 2009
… real estate in 2009, we are sticking with our negative stance on iStar Financial SFI, Chimera Investment CIM, Deerfield Capital DFR , Gramercy Capital GKK, Newcastle Investment NCT, and Alesco Financial AFN. We recently pulled our fair value …